Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PainReform (PRFX)
NASDAQ:PRFX
PRFX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.73 - $61.24
Previous CloseN/A
Volume49.01K
Average Volume (3M)2.20M
Market Cap
$3.04M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Feb 28, 2025EPS Estimate
-7.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.29
Shares Outstanding874,862
10 Day Avg. Volume4,493,006
30 Day Avg. Volume2,203,151
Standard Deviation0.22
R-Squared0.02
Alpha-0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
---
PainReform News
PremiumCompany Announcements
PainReform Diversifies with Acquisition of AI Solar Platform DeepSolar
PremiumCompany Announcements
PainReform Ltd. Gains $3.17 Million from Warrant Exercise
PremiumCompany Announcements
PainReform Faces Setback in Phase 3 Trial for PRF-110
---
Bulls Say, Bears Say
Bulls Say
Product DevelopmentPRF-110 was found to statistically significantly reduce pain over the first 48-hours.
Bears Say
Financial PerformancePainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.
---
Ownership Overview
―
Insiders
0.22%
Mutual Funds
1.48% Other Institutional Investors
98.52% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PRFX FAQ
What was PainReform’s price range in the past 12 months?
PainReform lowest stock price was $1.73 and its highest was $61.24 in the past 12 months.
What is PainReform’s market cap?
PainReform’s market cap is $3.04M.
When is PainReform’s upcoming earnings report date?
PainReform’s upcoming earnings report date is Feb 28, 2025 which is in 7 days.
How were PainReform’s earnings last quarter?
PainReform released its earnings results on Nov 12, 2024. The company reported -$18.96 earnings per share for the quarter, the consensus estimate of -$18.96 by $0.
Is PainReform overvalued?
According to Wall Street analysts PainReform’s price is currently Overvalued.
Does PainReform pay dividends?
PainReform does not currently pay dividends.
What is PainReform’s EPS estimate?
PainReform’s EPS estimate is -7.68.
How many shares outstanding does PainReform have?
PainReform has 874,862 shares outstanding.
What happened to PainReform’s price movement after its last earnings report?
PainReform reported an EPS of -$18.96 in its last earnings report, expectations of -$18.96. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PainReform?
Currently, no hedge funds are holding shares in PRFX
---
Company Description
PainReform
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
---
PRFX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---